Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial by Goldberg, Sarah B, MD, Schalper, Kurt A, MD, Gettinger, Scott N, Prof, Mahajan, Amit, MD, Herbst, Roy S, Prof, Chiang, Anne C, MD, Lilenbaum, Rogerio, Prof, Wilson, Frederick H, MD, Omay, Sacit Bulent, MD, Yu, James B, Prof, Jilaveanu, Lucia, PhD, Tran, Thuy, MD, Pavlik, Kira, MPH, Rowen, Elin, MSN, Gerrish, Heather, BSN, Komlo, Annette, MBA, Gupta, Richa, BS, Wyatt, Hailey, BS, Ribeiro, Matthew, BS, Kluger, Yuval, Prof, Zhou, Geyu, BSc, Wei, Wei, PhD, Chiang, Veronica L, Prof, Kluger, Harriet M, Prof

Get full text

A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study by Lu, Cheng, PhD, Bera, Kaustav, MD, Wang, Xiangxue, MD, Prasanna, Prateek, PhD, Xu, Jun, PhD, Janowczyk, Andrew, PhD, Beig, Niha, PhD, Yang, Michael, MD, Fu, Pingfu, PhD, Lewis, James, MD, Choi, Humberto, MD, Schmid, Ralph A, MD, Berezowska, Sabina, MD, Schalper, Kurt, MD, Rimm, David, MD, Velcheti, Vamsidhar, MD, Madabhushi, Anant, Prof

Get full text

Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study by Riess, Jonathan W., Lara, Matthew S., Lopez de Rodas, Miguel, Luxardi, Guillaume, Herbert, Samantha, Shimoda, Michiko, Kelly, Karen, Meerlev, Alexander, Moore, Elizabeth, Beckett, Laurel, Monjazeb, Arta, Schalper, Kurt, Maverakis, Emanual, Gandara, David R.

Get full text